FIELD: chemistry.
SUBSTANCE: present invention relates to four defined crystalline polymorphous forms of the monohydrate of a compound A having the following chemical composition:
.
Compound A. These four polymorphous forms, denoted here as forms I, II, III and IV, exhibit CXC chemokine receptor ligand activity.
EFFECT: invention relates to a pharmaceutical composition based on said compounds, to use thereof for treating different diseases and to methods for synthesising the said polymorphous forms.
58 cl, 2 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE POLYMORPHOUS FORM OF THROMBIN RECEPTOR ANTAGONIST BISULFATE | 2005 |
|
RU2355689C9 |
| CRYSTAL SUBSTANCE OF HETEROCYCLIDENACETAMIDE DERIVATIVE | 2018 |
|
RU2779198C2 |
| CRYSTALLINE FORMS OF KNOWN PYRROLIDINE INHIBITOR OF XA FACTOR | 2006 |
|
RU2368610C2 |
| TETOMILAST POLYMORPHS | 2007 |
|
RU2441002C2 |
| TETOMILAST POLYMORPHS | 2007 |
|
RU2408597C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINE[5,4,3-CD]INDOL-6-ON PHOSPHATE | 2005 |
|
RU2355691C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| CRYSTALLINE SOLID FORM OF A BENZENE SULPHONIC ACID SALT AND 2-[(4S)-6-(4-CHLOROPHENYL)-1-METHYL-8-(METHYLOXY)-4H-[1,2,4]TRIAZOLO[4,3-A][1,4]BENZODIAZEPIN-4-YL]-N-ETHYLACETAMIDE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2015 |
|
RU2697393C2 |
| NOVEL 951 COMPOUNDS: BIPHENYLOXYPROPANOIC ACID AS CRTh2 RECEPTOR MODIFIER AND INTERMEDIATE COMPOUNDS | 2008 |
|
RU2472785C2 |
| POLYMORPHIC FORMS OF ICOTINIB AND USES THEREOF | 2014 |
|
RU2710013C2 |
